TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23754736

Group type: EXPERIMENTAL
Intervention: Sifalimumab administered every 14 days as a 30- to 60-minute intravenous infusion with escalating doses of 0.3, 1.0, 3.0, and 10 mg/kg.
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Fixed dosing of sifalimumab at 200, 600, and 1,200 mg monthly (with a loading dose at Day 14).
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Population pharmacokinetic model of sifalimumab.
Number of subjects: 120
Study: 21542414

Group type: EXPERIMENTAL
Intervention: Denosumab
Number of subjects: 1564

Group type: COMPARATOR
Intervention: Zoledronic acid
Number of subjects: 1564

Group type: EXPERIMENTAL
Intervention: Denosumab and Zoledronic acid
Number of subjects: 1564
Study: 20183195

Group type: EXPERIMENTAL
Intervention: Methylmercury exposure through fish consumption
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Occupation (small-scale gold mining)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fish consumption
Number of subjects: 0

Group type: COMPARATOR
Intervention: Comparison with Brazilian studies
Number of subjects: 0
Study: 19442337

Group type: EXPERIMENTAL
Intervention: Music therapy
Number of subjects: 0
Study: 12950579

Group type: EXPERIMENTAL
Intervention: Profile nickel‐titanium rotary instrument system
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Hero 642 nickel‐titanium rotary instrument system
Number of subjects: 26
Study: 11130382

Group type: EXPERIMENTAL
Intervention: Pravastatin 40 mg daily
Number of subjects: 3260

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3260
Study: 9414336

Group type: COMPARATOR
Intervention: Standard keyboard
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Alternative keyboard designs (e.g. split keyboard, laterally inclined halves)
Number of subjects: 50
Study: 8466068

Group type: EXPERIMENTAL
Intervention: Intravenous bolus of regular insulin (20 u) followed by a glucose infusion (500 ml 5% dextrose in water) over 15 min
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Intravenous bolus of regular insulin (20 u)
Number of subjects: 40
Study: 3082644

Group type: EXPERIMENTAL
Intervention: Fluvoxamine, 50 mg twice a day
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Mianserin, 20 mg twice a day
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 31790563

Group type: EXPERIMENTAL
Intervention: Baseline PiB SUVR
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Change in PiB SUVR
Number of subjects: 175
Study: 29617064

Group type: EXPERIMENTAL
Intervention: Antidepressant medication alone
Number of subjects: 395

Group type: EXPERIMENTAL
Intervention: Antidepressant medication with CGT
Number of subjects: 395

Group type: EXPERIMENTAL
Intervention: CGT
Number of subjects: 395

Group type: EXPERIMENTAL
Intervention: CGT for SB participants
Number of subjects: 395

Group type: EXPERIMENTAL
Intervention: Other outcomes for SB participants
Number of subjects: 395
Study: 26970401

Group type: EXPERIMENTAL
Intervention: Certified nurse‐midwife telephone‐administered interpersonal psychotherapy (CNM‐IPT) sessions (up to eight 50-minute sessions)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Control group referred to mental health professionals
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: CNM‐IPT
Number of subjects: 61
Study: 25424297

Group type: EXPERIMENTAL
Intervention: Fentanyl (25 µg) combined with hyperbaric bupivacaine 0.5% (10mg)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Sufentanil (5.0 µg) combined with hyperbaric bupivacaine 0.5% (10mg)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Both groups (Fentanyl and Sufentanil)
Number of subjects: 64
Study: 21424698

Group type: EXPERIMENTAL
Intervention: sorafenib with gemcitabine (arm B)
Number of subjects: 37

Group type: COMPARATOR
Intervention: sorafenib alone (arm A)
Number of subjects: 37
Study: 19671919

Group type: EXPERIMENTAL
Intervention: Romiplostim
Number of subjects: 271
Study: 17572323

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (DEX)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Remifentanil (REM)
Number of subjects: 30
Study: 12951862

Group type: EXPERIMENTAL
Intervention: Etanercept (25 mg, twice-weekly subcutaneous injections for 4 months)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 11121908

Group type: EXPERIMENTAL
Intervention: Esomeprazole 20 mg twice daily (EAC)
Number of subjects: 448

Group type: COMPARATOR
Intervention: Omeprazole 20 mg twice daily (OAC)
Number of subjects: 448
Study: 9124240

Group type: EXPERIMENTAL
Intervention: Polymethylmethacrylate
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Silicone
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Soft acrylic
Number of subjects: 240
Study: 7645790

Group type: EXPERIMENTAL
Intervention: Midazolam (Versed), 0.4 mg/kg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Ketamine (Ketalar), 3 mg/kg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Sufentanil (Sufenta), 1.5 micrograms/kg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Sufentanil (Sufenta), 1.0 microgram/kg
Number of subjects: 30
Study: 3099943

Group type: EXPERIMENTAL
Intervention: Oral acyclovir 800 mg five times daily for seven days
Number of subjects: 205
Study: 31167867

Group type: EXPERIMENTAL
Intervention: Caseworker-delivered multicomponent intervention (behavioural counselling, nicotine spray, referral to Quitline and primary care)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 0
Study: 30265329

Group type: COMPARATOR
Intervention: No biopsy and no artificial shrinkage (Clinic 1)
Number of subjects: 2129

Group type: EXPERIMENTAL
Intervention: Trophectoderm biopsy and vitrification of collapsed blastocyst within 30 min (Clinics 1 and 2)
Number of subjects: 2129

Group type: EXPERIMENTAL
Intervention: No biopsy but laser-assisted artificial shrinkage (Clinic 2)
Number of subjects: 2129

Group type: EXPERIMENTAL
Intervention: Poor morphological quality pre-vitrification
Number of subjects: 2129

Group type: EXPERIMENTAL
Intervention: Taking 7 days to reach full blastulation
Number of subjects: 2129

Group type: EXPERIMENTAL
Intervention: Average morphological quality
Number of subjects: 2129

Group type: EXPERIMENTAL
Intervention: Poor morphological quality
Number of subjects: 2129

Group type: EXPERIMENTAL
Intervention: Prevention of spontaneous hatching pre-vitrification
Number of subjects: 2129

Group type: EXPERIMENTAL
Intervention: Poor-quality blastocysts pre-vitrification
Number of subjects: 2129
Study: 27460692

Group type: EXPERIMENTAL
Intervention: 40 Hz/high amplitude (40H)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 50 Hz/low amplitude (50L)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 50 Hz/high amplitude (50H)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: All WBV protocols
Number of subjects: 16
Study: 25266182

Group type: EXPERIMENTAL
Intervention: Off-pump coronary artery bypass grafting (OPCAB)
Number of subjects: 102

Group type: COMPARATOR
Intervention: On-pump coronary artery bypass grafting (ONCAB)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Both OPCAB and ONCAB
Number of subjects: 102
Study: 23327023

Group type: EXPERIMENTAL
Intervention: Gargling with ketamine 40 mg in 30 ml saline for 60 seconds (Group K)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: 0.05% betamethasone gel applied over endotracheal tube (Group B)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control group (Group C)
Number of subjects: 75
Study: 20874515

Group type: EXPERIMENTAL
Intervention: 7.5 μg of H1N1 hemagglutinin vaccine
Number of subjects: 1313

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1313
Study: 17207457

Group type: EXPERIMENTAL
Intervention: Exposure plus response-prevention (E/RP)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Wait-list condition (Control)
Number of subjects: 20
Study: 15942235

Group type: EXPERIMENTAL
Intervention: Cloxacillin (2 g/day)
Number of subjects: 334

Group type: COMPARATOR
Intervention: Pristinamycin (2 g/day)
Number of subjects: 334

Group type: EXPERIMENTAL
Intervention: Cloxacillin
Number of subjects: 334

Group type: COMPARATOR
Intervention: Pristinamycin
Number of subjects: 334
Study: 12649032

Group type: EXPERIMENTAL
Intervention: Knee flexed to 70 degrees for 6 h post-operatively (Group 2)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Leg elevated 35 degrees at the hip with knee extended for 6 h post-operatively (Group 3)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Knee extended and level with bed (Group 1)
Number of subjects: 60
Study: 10472877

Group type: EXPERIMENTAL
Intervention: High-dose oxytocin (4.5 mU/minute initially, increased by 4.5 mU/minute every 30 minutes) for induction
Number of subjects: 1307

Group type: COMPARATOR
Intervention: Low-dose oxytocin (1.5 mU/minute initially, increased by 1.5 mU/minute every 30 minutes) for induction
Number of subjects: 1307

Group type: EXPERIMENTAL
Intervention: High-dose oxytocin for augmentation
Number of subjects: 1307

Group type: COMPARATOR
Intervention: Low-dose oxytocin for augmentation
Number of subjects: 1307

Group type: EXPERIMENTAL
Intervention: High-dose oxytocin for induction in nulliparous women
Number of subjects: 1307

Group type: COMPARATOR
Intervention: Low-dose oxytocin for induction in nulliparous women
Number of subjects: 1307

Group type: EXPERIMENTAL
Intervention: High-dose oxytocin for induction in nulliparous women (cephalopelvic disproportion)
Number of subjects: 1307

Group type: COMPARATOR
Intervention: Low-dose oxytocin for induction in nulliparous women (cephalopelvic disproportion)
Number of subjects: 1307
Study: 8912741

Group type: EXPERIMENTAL
Intervention: Patients with COPD
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 27
Study: 1862062

Group type: EXPERIMENTAL
Intervention: Normative education alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Resistance skill training alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both resistance skill training and normative education
Number of subjects: 0

Group type: COMPARATOR
Intervention: Neither of the experimental curricula (placebo comparison)
Number of subjects: 0
Study: 6627821

Group type: EXPERIMENTAL
Intervention: Caffeine (50 to 800 mg)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: d-Amphetamine sulfate (25 mg)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 28351446

Group type: EXPERIMENTAL
Intervention: Prenatal supplementation with fish oil and/or 5-methyltetrahydrofolate
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Head circumference at 4 years
Number of subjects: 74
Study: 28523223

Group type: EXPERIMENTAL
Intervention: tDCS during extinction consolidation
Number of subjects: 28

Group type: COMPARATOR
Intervention: tDCS during extinction learning
Number of subjects: 28
Study: 27129759

Group type: EXPERIMENTAL
Intervention: Showering at 2 days postoperatively
Number of subjects: 32

Group type: COMPARATOR
Intervention: Showering at 2 weeks postoperatively
Number of subjects: 32
Study: 24418365

Group type: EXPERIMENTAL
Intervention: Androgen deprivation therapy (ADT) for 18 months without bisphosphonates
Number of subjects: 123

Group type: COMPARATOR
Intervention: Shorter androgen deprivation therapy (ADT) course combined with bisphosphonates
Number of subjects: 123

Group type: COMPARATOR
Intervention: Prostate cancer patients with only nodal metastases or BF
Number of subjects: 123

Group type: COMPARATOR
Intervention: Patients who did not experience biochemical failure (BF)
Number of subjects: 123
Study: 23078756

Group type: EXPERIMENTAL
Intervention: Targeted treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Initial combination therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Patients who lost drug free remission
Number of subjects: 0
Study: 19324974

Group type: EXPERIMENTAL
Intervention: Simvastatin 40 mg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Simvastatin 80 mg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Simvastatin (40 mg or 80 mg)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Simvastatin
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 17562956

Group type: EXPERIMENTAL
Intervention: Isolation of large areas around both ipsilateral pulmonary veins (group II)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Isolation of each individual pulmonary vein (group I)
Number of subjects: 110
Study: 12853502

Group type: EXPERIMENTAL
Intervention: Inhaled triamcinolone, 1,200 microg daily
Number of subjects: 221

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 221
Study: 10214011

Group type: EXPERIMENTAL
Intervention: Combined epidural and general anesthesia (Group A and C)
Number of subjects: 135

Group type: COMPARATOR
Intervention: General anesthesia (Group B and D)
Number of subjects: 135
Study: 8538705

Group type: EXPERIMENTAL
Intervention: Two-component acellular DTP vaccine (2566 children)
Number of subjects: 9829

Group type: EXPERIMENTAL
Intervention: Five-component acellular DTP vaccine (2587 children)
Number of subjects: 9829

Group type: EXPERIMENTAL
Intervention: Whole-cell DTP vaccine (2102 children)
Number of subjects: 9829

Group type: COMPARATOR
Intervention: Control group (DT vaccine, 2574 children)
Number of subjects: 9829

Group type: EXPERIMENTAL
Intervention: Whole-cell vaccine
Number of subjects: 9829
Study: 2070378

Group type: EXPERIMENTAL
Intervention: NH4F treatment
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: NaF treatment
Number of subjects: 58

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 58
Study: 7055433

Group type: EXPERIMENTAL
Intervention: 12 hours of penicillin G potassium and doxycycline hyclate
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: 5 days of penicillin G potassium and doxycycline hyclate
Number of subjects: 82

Group type: COMPARATOR
Intervention: Control group (no intestinal penetration)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: 12 hours and 5 days of antibiotics
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Intestinal penetration
Number of subjects: 82
Study: 31782032

Group type: EXPERIMENTAL
Intervention: Intermittent chemotherapy (two times four cycles)
Number of subjects: 398

Group type: COMPARATOR
Intervention: Continuous chemotherapy (eight subsequent cycles)
Number of subjects: 398
Study: 31003136

Group type: EXPERIMENTAL
Intervention: Trier Social Stress Test for Groups (TSST-G)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Non-stressful control condition
Number of subjects: 70
Study: 28860402

Group type: EXPERIMENTAL
Intervention: Targon PFT nail
Number of subjects: 400

Group type: COMPARATOR
Intervention: Sliding hip screw (SHS)
Number of subjects: 400
Study: 25985446

Group type: EXPERIMENTAL
Intervention: AI/2-CDA (6 mg/m²/d, days 1, 3) in combination with cytarabine/idarubicin (AI=500 mg/m² cytarabine 5 days continuous infusion plus 7 mg/m²/d idarubicin, days 3 and 5)
Number of subjects: 343

Group type: COMPARATOR
Intervention: AI (500 mg/m² cytarabine 5 days continuous infusion plus 7 mg/m²/d idarubicin, days 3 and 5)
Number of subjects: 343
Study: 23303767

Group type: EXPERIMENTAL
Intervention: Intervention group (12 weeks of exercise training and 1 year of psycho-educational follow-up)
Number of subjects: 196

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 196
Study: 21735660

Group type: EXPERIMENTAL
Intervention: Integrated therapy of traditional Chinese and Western medicine
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control group (transurethral plasmakentic vaporization, anti-infection, rehydration, and supportive therapies)
Number of subjects: 52
Study: 19906345

Group type: EXPERIMENTAL
Intervention: 20 mg/d memantine
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 17012721

Group type: EXPERIMENTAL
Intervention: Adper Scotchbond Multipurpose Dental Adhesive (SBMP)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Clearfil SE Bond (CFSE)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Prime & Bond NT (PBNT)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: PQ1
Number of subjects: 10
Study: 16244759

Group type: EXPERIMENTAL
Intervention: Hearing aid intervention
Number of subjects: 380
Study: 10507241

Group type: EXPERIMENTAL
Intervention: Amoxapine formulation 1
Number of subjects: 0

Group type: COMPARATOR
Intervention: Amoxapine formulation 2
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 8-hydroxyamoxapine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 7-hydroxyamoxapine
Number of subjects: 0
Study: 8735578

Group type: EXPERIMENTAL
Intervention: Clomipramine
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 1755739

Group type: EXPERIMENTAL
Intervention: PhXA34 1 microgram
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: PhXA34 3 micrograms
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: PhXA34 10 micrograms
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: PhXA34 10 micrograms once daily for 7 days
Number of subjects: 2
Study: 6124474

Group type: EXPERIMENTAL
Intervention: Metronidazole
Number of subjects: 78

Group type: COMPARATOR
Intervention: Sulfasalazine
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Metronidazole (after crossover)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Sulfasalazine (after crossover)
Number of subjects: 78
Study: 31577070

Group type: EXPERIMENTAL
Intervention: Arthrocentesis plus platelet-rich plasma (PRP)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Arthrocentesis plus hyaluronic acid (HA)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Arthrocentesis only (control)
Number of subjects: 30
Study: 29637837

Group type: EXPERIMENTAL
Intervention: Aligned teeth
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Maxillary stainless steel labial fixed appliance
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Absent maxillary left lateral incisor
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (no specific intervention)
Number of subjects: 90
Study: 27106176

Group type: EXPERIMENTAL
Intervention: Lyophilisate formulation
Number of subjects: 47

Group type: COMPARATOR
Intervention: Tablet formulation
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Fasted state
Number of subjects: 47

Group type: COMPARATOR
Intervention: Fed state
Number of subjects: 47
Study: 24698570

Group type: EXPERIMENTAL
Intervention: CO2 fractional laser plus radiofrequency
Number of subjects: 10

Group type: COMPARATOR
Intervention: CO2 fractional laser
Number of subjects: 10
Study: 23146788

Group type: EXPERIMENTAL
Intervention: Newly diagnosed type 1 diabetes (DMT1) patients immediately after treatment of diabetic ketoacidosis (study I)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Control group (children without symptoms suggestive of urolithiasis)
Number of subjects: 140
Study: 19747796

Group type: EXPERIMENTAL
Intervention: Disgust conditioning and extinction procedure
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Disgust sensitivity
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Expectancy of the disgusting US during extinction
Number of subjects: 0
Study: 17918321

Group type: COMPARATOR
Intervention: Standard cardiotropic therapy (nitrates, beta-blockers, ACE inhibitors on demand, diuretics, antioxidants) and placebo
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Standard cardiotropic therapy plus impase (1 tablet every other day for 3 months)
Number of subjects: 58
Study: 16159592

Group type: EXPERIMENTAL
Intervention: CBTgsh
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: BWLgsh
Number of subjects: 90

Group type: COMPARATOR
Intervention: CON
Number of subjects: 90
Study: 12018633

Group type: EXPERIMENTAL
Intervention: Phosphate levels
Number of subjects: 638

Group type: EXPERIMENTAL
Intervention: Calcium levels
Number of subjects: 638

Group type: EXPERIMENTAL
Intervention: Ca x P levels
Number of subjects: 638

Group type: EXPERIMENTAL
Intervention: Alkaline phosphatase levels
Number of subjects: 638

Group type: EXPERIMENTAL
Intervention: Intact parathyroid hormone (PTH) levels
Number of subjects: 638
Study: 10050221

Group type: EXPERIMENTAL
Intervention: Intravenous midazolam 1.0 mg/h
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 7720852

Group type: EXPERIMENTAL
Intervention: School-based AIDS risk-reduction program
Number of subjects: 2392

Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 2392
Study: 2041927

Group type: EXPERIMENTAL
Intervention: Erythromycin tablets (Abboticin 500 mg tablets)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Fusidic acid cream (Fucidin cream)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study: 30973426

Group type: EXPERIMENTAL
Intervention: Exposure to incivility
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not exposed to incivility)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both groups (experimental and control)
Number of subjects: 0
Study: 31438925

Group type: EXPERIMENTAL
Intervention: Brief mindfulness-based intervention (MBI), four sessions in total
Number of subjects: 154

Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Brief mindfulness-based intervention (MBI)
Number of subjects: 154
Study: 28077611

Group type: EXPERIMENTAL
Intervention: Umbilical Venous Catheter (UVC)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Peripherally Inserted Central Catheter (PICC)
Number of subjects: 72
Study: 26260018

Group type: EXPERIMENTAL
Intervention: CO2 fractional laser treatment (3 sessions every 4-6 weeks)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: CO2 fractional laser treatment
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control (untreated half of the scar)
Number of subjects: 15
Study: 23739686

Group type: EXPERIMENTAL
Intervention: Cryotherapy (CRYO) - 3 × 4 minutes at -30°C
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control (CONT)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Cryotherapy (CRYO)
Number of subjects: 24
Study: 21747289

Group type: EXPERIMENTAL
Intervention: Oral rehydration (OR) with D2O labeled fluid
Number of subjects: 10

Group type: COMPARATOR
Intervention: Oral combined with intravenous rehydration (IVO) with D2O labeled fluid
Number of subjects: 10
Study: 20011886

Group type: EXPERIMENTAL
Intervention: Aprotinin
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control
Number of subjects: 19
Study: 17550955

Group type: EXPERIMENTAL
Intervention: eMPC (enhanced model predictive control)
Number of subjects: 60

Group type: COMPARATOR
Intervention: RMP (routine glucose management protocol)
Number of subjects: 60